Results 41 to 50 of about 47,434 (363)

Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements

Cells, 2019
In recent years, the introduction of new molecular techniques in experimental and clinical settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) analysis and liquid biopsy as novel promising strategies for the early ...
Natalia O. Tuaeva, Luca Falzone, Yuri B. Porozov, Alexander E. Nosyrev, Vladimir M. Trukhan, Leda Kovatsi, Demetrios A. Spandidos, Nikolaos Drakoulis, Alexandra Kalogeraki, Charalampos Mamoulakis, George Tzanakakis, Massimo Libra, Aristides Tsatsakis   +12 more
doaj   +1 more source

Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]

, 2019
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca, Cortesi, Enrico, Gazzaniga, Paola, Gelibter, ALAIN JONATHAN, Giannini, Giuseppe, Gradilone, Angela, Loreni, Flavia, Mahdavia, Yasaman, Nicolazzo, Chiara, Raimondi, Cristina   +9 more
core   +1 more source

The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization

Medizinische Genetik, 2023
Liquid biopsies, in particular the profiling of circulating tumor DNA (ctDNA), have long held promise as transformative tools in cancer precision medicine.
A. Bronkhorst, S. Holdenrieder
semanticscholar   +1 more source

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Cancer Biology & Medicine, 2021
Objective: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer.
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan   +13 more
doaj   +1 more source

EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment [PDF]

, 2018
A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening ...
Cortesi, Enrico, Gazzaniga, Paola, Raimondi, Cristina, Urbano, Federica   +3 more
core   +1 more source

Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients

Cancer Research, Statistics, and Treatment, 2019
Background: Outcomes based on liquid biopsy in poor performance, older, biopsy-ineligible advanced non-small cell lung cancer (NSCLC) patients are unknown.
Avinash Pandey, Sarjana Dutt, Anjana Singh, Amit Kumar, Shivkant Singh   +4 more
doaj   +1 more source

Circulating biomarkers in malignant pleural mesothelioma

Exploration of Targeted Anti-tumor Therapy, 2020
Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage.
Giuseppe Viscardi, Davide Di Natale, Morena Fasano, Marta Brambilla, Riccardo Lobefaro, Alessandro De Toma, Giulia Galli   +6 more
doaj   +1 more source

Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives [PDF]

, 2019
Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high
Campisi, Giuseppina, Cristaldi, Marta, Di Fede, Olga, Giuliana, Giovanna, Mauceri, Rodolfo, Panzarella, Vera   +5 more
core   +1 more source

A mathematical model of ctDNA shedding predicts tumor detection size [PDF]

Science Advances, 2020
A mathematical model of tumor evolution and ctDNA shedding informs new cancer early detection approaches. Early cancer detection aims to find tumors before they progress to an incurable stage.
Stefano Avanzini, David M. Kurtz, Jacob J. Chabon, Everett J. Moding, Sharon S. Hori, Sanjiv S. Gambhir, Ash A. Alizadeh, Maximilian Diehn, Johannes G. Reiter   +8 more
openalex   +2 more sources

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC

Nature Communications, 2021
Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluate the clinical utility of circulating tumor DNA ...
B. Qiu, Wei Guo, Fanshuang Zhang, Fang Lv, Ying Ji, Yue Peng, Xiaoxi Chen, H. Bao, Yang Xu, Y. Shao, F. Tan, Q. Xue, Shugeng Gao, Jie He   +13 more
semanticscholar   +1 more source